Novartis/Alcon: why the last 23% is worth the extra mile
This article was originally published in Scrip
Why is Novartis so doggedly pursuing full ownership of Alcon, an M&A transaction that rates among the most protracted the Swiss pharma group has ever undertaken?
You may also be interested in...
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.